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Abstract 
Patients with low-grade glioma frequently have brain tumor-related epilepsy, which is more common than 
in patients with high-grade glioma. Treatment for tumor-associated epilepsy usually comprises a 
combination of surgery, antiepileptic drugs (AEDs), chemotherapy and radiotherapy. Response to tumor-
directed treatment is measured primarily by overall survival and progression-free survival. However, 
seizure frequency has been observed to respond to tumor-directed treatment with chemotherapy or 
radiotherapy. A review of the current literature regarding seizure assessment for low-grade glioma 
patients reveals a heterogeneous manner in which seizure response has been reported. There is a need for 
a systematic approach to seizure assessment and its influence on health-related quality-of-life outcomes in 
patients enrolled in low-grade glioma therapeutic trials. In view of the need to have an adjunctive metric 
of tumor response in these patients, a method of seizure assessment as a metric in brain tumor treatment 
trials is proposed. 
 
Key words:  Seizures, metric, low-grade, glioma, scale 
 
Importance of the Study:  This position paper will describe the importance of developing a metric to 
assess seizure frequency in brain tumor treatment trials.  Seizure frequency can affect many aspects of a 
patient’s life including vocation and the ability to drive.  Seizure control can be achieved through 
treatment of low-grade glioma and is seen after gross total resection, chemotherapy or radiotherapy.  As 
such, seizures can be a surrogate marker for treatment response in patients with low-grade glioma and 
may serve as an important secondary endpoint.  The current paper will propose a new method in which 
seizure assessment can occur in low-grade glioma treatment trials.    
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Introduction 
Adults with low-grade glioma (LGG: World Health Organization [WHO] grade I and II gliomas) have a 
more favorable prognosis than those with higher grade gliomas (WHO grade III and IV), but ultimately 
most die of their disease. Current optimal treatment of adult WHO grade II gliomas results in a median 
overall survival (OS) of 7 years, (range 5-14 years), making health-related quality of life (HRQOL) an 
important outcome in this population of typically young adults.1  Seizures are reported in up to 60-80% of 
LGGs (WHO grade II gliomas) and 50-60% of WHO grade III anaplastic gliomas. Moreover, recent 
studies have suggested a higher seizure frequency at onset in gliomas expressing the isocitrate 
dehydrogenase (IDH) mutation findings seen in 70% of low-grade gliomas.2 HRQOL is highly affected 
by seizures and antiepileptic drugs (AEDs), and epilepsy can cause significant disability in patients with 
LGG.  Progression-free survival (PFS) and OS are the usual metrics of anti-tumor therapies; however, 
surrogate and clinically relevant determinants of outcome such as seizure control are pertinent in LGG.3  
  Localization-related epilepsy, as defined by the International League against Epilepsy (ILAE), 
causes unprovoked seizures from a discrete area of epileptogenic brain.4 This is the type of epilepsy 
which arises in patients with LGG where the epileptic focus usually originates from brain immediately 
surrounding the tumor, the so-called peri-tumoral brain region.5 However, the epileptic zone often 
includes regions well beyond the visible tumor margin.6  The unpredictability of epilepsy affects the 
patient’s psychological and functional well-being, and can compromise numerous activities of daily living 
including but not limited to driving, working with machinery, and swimming.  A patient’s HRQOL is 
particularly affected when seizures are uncontrolled, which occurs in up to 30% of patients with brain 
tumor-related epilepsy (BTRE).7  In addition, AEDs can have a negative effect on self-reported HRQOL 
measures, particularly in those on polypharmacy or those on AEDs for greater than 6 months.8 
Furthermore, AEDs may be a significant cause of impaired cognition in LGG patients which can often 
have a greater adverse impact than the underlying tumor or prior cranial radiotherapy (RT).9  Taken 
together, these data suggest that both seizures and their treatment can significantly compromise 
HRQOL.10  
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The importance of measuring seizure control in brain tumor trials 
Control of seizures has a direct relationship to HRQOL, driving, vocation, sexual activity, and mood.11-13  
Patients whose seizures are well controlled also have lower morbidity and mortality,  such as sudden 
unexpected death in epilepsy (SUDEP) compared to patients with uncontrolled epilepsy (incidence of 
1/1,000 in poorly controlled versus  1/150 in well controlled).14,15 Seizure control is the primary endpoint 
in trials examining novel therapeutics in epilepsy.  Why then should it be an endpoint in assessing brain 
tumor therapies?  Uncontrolled seizures have a major impact on a patient’s function.  Brain tumor 
treatments are assessed by their direct effect on survival and the disease itself as measured by 
neuroimaging, but radiographic regression in LGG is typically slow and often difficult to measure.  In 
contrast,  seizure frequency is quantifiable and may serve as a surrogate marker of tumor response 
although this is still being investigated.16  Inadequate seizure control, even without radiographic evidence 
of tumor progression, has been  used as a reason to initiate further treatment of a LGG and loss of seizure 
control can be an early indicator of tumor progression.17 Likewise, restoration of seizure control may be 
the first indicator that a therapy is effective.16,17 In addition, for patients with poorly controlled seizures, 
the majority of whom have normal or non-progressive neurologic exams, seizure control is often the only 
clinical parameter that is clinically relevant.  Thus, it is important to consider seizure control when 
assessing a new tumor-directed therapy – not to replace the standard measures of tumor response (PFS 
and OS) but to quantify clinical outcomes, to potentially identify an early signal of anti-glioma efficacy, 
and to establish quality of survival.  This could be particularly relevant when investigating novel 
compounds that target common pathways of epileptogenesis and tumor cell proliferation such as the use 
of rapamycin in tuberous sclerosis complex.18,19 Thus, it is important to standardize the methods used for 
such a determinant in patients with LGG and epilepsy.  The following review will outline seizure 
outcomes after tumor-directed treatments and the manner in which seizure outcome is determined in 
epilepsy trials.  The RANO (Response Assessment in Neuro-Oncology) seizure working group then 
proposes how this methodology can be implemented in LGG trials.   
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Seizure outcome after surgery 
Maximal glioma resection has been repeatedly shown to improve seizure control.  Whether the lesion is 
temporal or extra-temporal, an Engel class I (free of disabling seizures) is achieved in 80% of patients 
with maximal resection (Table 1).20,21 The manner in which a glioma is surgically treated differs from a 
resection performed specifically for non-tumor related epilepsy in which direct cortical recording or 
electrocorticography (ECoG) or extra-operative invasive methods are often used. These intraoperative 
techniques are not usually implemented during glioma surgery and may not be relevant for improving 
seizure outcomes in brain tumor patients, specifically when the BTRE syndrome is less than one year 
duration.22  However, utilization of an epilepsy surgery approach with extra-operative invasive recording 
for patients with BTRE can help to localize the epileptogenic zone, provide insight into pathophysiology 
of BTRE, and may lead to improved seizure-free outcomes.6 For WHO grade I temporal lobe tumors such 
as dysembryoplastic neuroepithelial tumor (DNET) or ganglioglioma, temporal lobectomy with 
hippocampectomy leads to a more favorable seizure outcome compared with excision of the lesion 
alone.23  However, complete tumor removal with or without hippocampectomy is rarely an option for the 
more common diffuse WHO grade II LGGs.  Rarely, seizures can appear or intensify after tumor 
resection.  
 
Seizure outcome after radiotherapy 
There have been several studies examining the response of seizures in LGG patients treated with RT. RT 
for LGG (age>40 years or incomplete resection) prolongs PFS but not OS if administered at initial 
diagnosis versus at progression.24  Seizure control has been evaluated as a secondary endpoint in RT trials 
including trials of brachytherapy, stereotactic radiosurgery and involved-field fractionated irradiation.24-28  
These studies examined many aspects of seizure response including seizure freedom, percentage of 
decrease compared to baseline seizure frequency, and improved Engel class.10  In a large trial of RT 
(group 1, early treatment, group 2, late treatment) seizure freedom at 12 months was reported in 75% of 
those with early RT and 59% of those treated with delayed RT given at the time of progression.24  In a 
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trial evaluating 30 patients with insular gliomas who received RT, Engel class I outcome was achieved in 
70% with only 3% at Engel class III after therapy.29  A large trial using fractionated stereotactic 
radiosurgery in 143 patients with LGG found a decrease in generalized seizures from 36% to 7% and a 
decrease in focal seizures from 34% to 17% six weeks after RT.30 However, it is important to note in this 
study the role of AEDs was rarely reported or considered, therefore ignoring the contribution of AEDs to 
seizure control.  A recent study analyzed the seizure outcome following conformal RT in a cohort of 43 
patients with grade II and III glioma and medically intractable epilepsy in whom AED treatment was 
recorded and not changed during the study period. A reduction of seizure frequency ≥ 50% was obtained 
in 72% and 76% at 3 and 6 month after RT, respectively, while seizure freedom was achieved at 12 
months in 32% of patients 25 
 
Seizure outcome after chemotherapy 
Recent studies strongly suggest a correlation between improved seizure control and benefit from 
chemotherapy for LGG. There are no randomized controlled trials examining this relationship, but there 
are several prospective as well as retrospective studies.10,31-35  The common theme has been that 
chemotherapy alone reduces seizure frequency irrespective of whether tumor response is measurable by 
neuroimaging.  Seizure control is observed regardless of the chemotherapy regimen (e.g. temozolomide or 
a nitrosourea-based therapy such as PCV [procarbazine, lomustine, and vincristine]).10 In a retrospective 
study of 66 patients with LGG who received temozolomide, 44% had improvement in seizure frequency 
with 41% achieving seizure freedom after 6 months.36  A small prospective trial of 10 patients with 
unresectable LGG treated with neoadjuvant temozolomide showed a seizure reduction of 90% with one-
half of patients achieving seizure freedom at an undefined follow-up period.37  A separate prospective 
study evaluated the response of seizures to temozolomide at 3 month periods during treatment; a 50% 
reduction in seizure frequency was reported in 48% of patients with 13% achieving seizure freedom at the 
end of the study.33 
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Seizure classification   
The ILAE has proposed several systems of classifying seizures and epilepsy syndromes since 1960.  The 
ILAE published an update on seizure classification in 1981 and on epilepsy syndromes in 1989.  More 
recently, new changes were suggested to reflect a more clinically based approach with inclusion of 
etiology;38  however, for the purposes of brain tumor trials, seizure semiology can be best classified using 
the 1989 system.  Seizures that arise from a brain tumor are all termed symptomatic, i.e. secondary to the 
underlying glioma.4  In addition, seizures can be classified as focal epilepsy with or without secondary 
generalization.  Seizures without secondary generalization can then be classified as either a simple partial 
seizure that manifests as motor, sensory, and/or visual abnormalities without alteration of consciousness, 
or as complex partial seizures that manifest as motor, sensory, and/or visual disturbances with alteration 
of consciousness.  In addition, all generalized seizures that arise in a brain tumor patient are partial in 
onset whether clinically evident or not.  Thus, even patients with a generalized tonic-clonic seizure at 
presentation likely have a focal onset and can be classified as secondarily generalized tonic-clonic or 
focal seizures evolving to a bilateral, convulsive seizure. The remainder of the ILAE classification system 
is not relevant in assessing seizures in brain tumor patients.   
The National Institute of Neurological Disorders and Stroke (NINDS) developed a seizure 
classification tool that is often used for AED trials.  Using this instrument, seizures are divided into 
generalized, focal or unclassified seizure type.  Each seizure type may have associated stereotypic 
movements such as myoclonic jerks, atonic movements, with or without loss of consciousness (Table 
2).38,39  In the brain tumor population, dividing seizures into secondarily generalized or focal (partial) 
would likely be most pragmatic.  Further stratification of seizures may make any assessment tool too 
cumbersome for routine use in brain tumor treatment trials where non-neurologists will play an important 
role in seizure assessment. 
 
Data collection approaches for seizures  
Counting seizures 
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Enumerating seizure frequency largely depends on patient reports.  In epilepsy drug trials, patients are 
provided with seizure diaries, which provide a log of seizure frequency permitting an assessment of 
seizures over a standardized period of time.  A seizure diary may be challenging for some patients with 
BTRE, either because of cognitive deficits or behavioral problems.  Some patients, such as those with 
significant aphasia or amnesia, may require a care provider to report seizure frequency.  Reliability is also 
a concern as recall bias may affect the actual number of reported seizures.  However, studies correlating 
patient and observer recall of seizures show a good concordance; up to 81% in patients without brain 
tumors.40,41  
Counting seizures can be challenging but the investigator can report seizure frequency in one of 
two ways: 1) the exact number of seizures, or 2)  a relative change in frequency (few, many, fewer, or 
more seizures) compared to baseline.42  The data can also be reported as a percentage change from 
baseline frequency or a change in rate over time.  A typical endpoint for AED trials is improvement in 
seizure rate by greater than 50% of baseline or seizure freedom.42  The recording of number of seizures, 
however, omits important information regarding the seizure qualities (intensity, duration and associated 
symptoms) or severity.  In addition, simple counting or reporting the rate of seizures does not give 
information regarding seizure type and considers all seizure types as equivalent.  For example, a simple 
partial seizure would be considered equivalent to a secondary generalized seizure despite the fact that the 
latter has a greater morbidity and likely a greater impact on HRQOL.  Therefore, seizure severity scales 
have been developed to capture qualitative information that could provide an assessment of drug efficacy 
on seizure type.   
The Engel scale was developed to compare seizure outcomes in patients who have undergone 
surgical resection of an epileptic focus including patients with BTRE (Table 1).  The benefit of this scale 
is that it can be compared across surgical trials for epilepsy surgery. 43 However, the use of this scale for 
non-surgical brain tumor treatment trials may prove difficult in view of some of the ambiguous 
terminology, specifically regarding Engel class III and IV. The determination of worthwhile improvement 
versus no worthwhile improvement is subjective and would likely differ from physician to physician. In 
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2001, the ILAE proposed a new classification of seizure outcome following epilepsy surgery (Table 3). 44 
The ILAE committee cited disadvantages of Engel’s classification including the ambiguous terminology 
and the lack of a clear percentage of seizure reduction, such as greater than 50% seizure reduction, which 
is commonly used in epilepsy drug trials. The ILAE classification tool would clearly identify seizure-free 
patients as well as those with greater than 50% reduction of baseline seizures.44 
All of the scales and studies collected clinical seizures, and did not include objective data such as 
EEG recordings.  Therefore, some seizures can be missed.  A prospective study of adult inpatients with 
focal epilepsy undergoing video-EEG monitoring compared patient seizure diaries to video-EEG 
recording.45 A significant discrepancy in seizure reporting was seen across all seizure types but most 
notably in complex partial and nocturnal seizures.  Patients failed to document 55.5% of all recorded 
seizures, 73.2% of complex partial seizures and 85.8% of nocturnal events. A left-sided EEG focus or 
lesion was predictive for underreporting, but no specific lobe of the brain was associated with 
underreporting.  This study highlights some of the limitations in assessing a response to tumor treatment 
by using patient-reported seizure frequency; however, EEG data are not used in the assessment of a novel 
AED and a clinical determination of efficacy, by whatever chosen method, is the standard in epilepsy 
trials. 
 
Seizure severity   
Seizure frequency as a metric can provide important information if seizure severity is also assessed.      
Several characteristics of seizures, including duration and intensity, are useful in assessing a response to 
treatment.  Patient or physician-reported seizure severity scales have been used to assess response of 
seizures to an AED.  These scales include many useful data points but no scale captures all the relevant 
clinical data, and thus, all are imperfect.   
In the Veterans Administration (VA) cooperative study, a seizure frequency and seizure severity 
scale was developed to be completed by a physician.46 Although this scale allows for significant detail to 
be gathered regarding generalized tonic-clonic and complex partial seizures, it has proven too complex 
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for widespread use.47  The Chalfont-National Hospital Scale (NHS3) was developed as a simpler version 
of the VA scale.  This scale was also devised to be completed by the physician and by those who 
witnessed the seizures.48  
The Occupational Hazard Scale evaluates seizure severity by assessing its impact on the patient’s 
function in society.49  The scale was used primarily to assess a patient’s ability to fulfill certain 
occupations.  The Liverpool Seizure Severity Scale is a patient reported scale.50  The patient completes a 
19-item questionnaire that is divided into two sections. The first section is perception of control and the 
second section includes ictal and postictal items. One potential limitation with this scale is that the 
patient’s memory of individual seizures, specifically those associated with alteration of consciousness, 
may not be as accurate as a witness’ recollection.51  Although minimal difference was seen in the 
perception scale, this study again demonstrated that the perception scale was not as useful as the ictal 
scale. The Hague Seizure Severity Scale (HASS) was developed for children.52  This was a questionnaire 
designed to be completed by parents only. Correlation between parent’s and neurologist’s scores showed 
comparable results but were not significant after stratification for seizure type. 
A comparison of the different scales including the VA, NHS3, Occupational Hazard, Liverpool 
and HASS shows numerous similarities in items that are assessed (Table 4).  For example, all of the 
severity scales assess seizure type but not in the same manner. The VA Scale assesses simple partial 
seizures, complex partial and generalized tonic-clonic seizures whereas the Liverpool Scale assesses all 
types of seizures. Surprisingly, not all scales include an assessment of seizure frequency. Seizure 
frequency is not a direct measure in the NHS3, Liverpool or HASS classifications.  The rating scales are 
also arbitrary and subjective. There are no data associating specific severity scores of scales with a need 
to change therapy or confirming appropriate therapy.  Importantly, there have not been any studies in 
glioma patients with epilepsy using severity scales for seizure assessment.  Thus, the value of these scales 
in patients with LGG and BTRE is unknown.  
 
Health-Related Quality of Life Measures and Symptom Burden.  
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There are several established HRQOL measures and symptom severity scales for patients with brain 
tumors.  Commonly used tools are the European Organization for Research and Treatment of Cancer 
(EORTC) QLQ30 combined with the brain tumor module (BN20), the Functional Assessment of Cancer 
Therapy-brain (FACT-Br), the Functional Assessment of Cancer Therapy-general (FACT-G) and the 
M.D. Anderson Symptom Inventory – Brain Tumor (MDASI-BT).53 These HRQOL measures have been 
used in large brain tumor treatment trials to assess a subjective response to brain tumor treatment.  Similar 
patient reported outcome measures are used in AED trials.   
A commonly used tool in epilepsy trials is the Quality Of Life in Epilepsy (QOLIE-31).  This is a 
validated tool that has been used in cross cultural clinical trials assessing HRQOL as it pertains to seizure 
control.54 Several of the HRQOL tools used in brain tumor treatment trials capture a limited amount of 
information regarding seizures.  For example, the FACT-Br, BN20, and MDASI-BT include 1-2 seizure 
questions (Table 5).  HRQOL measures in brain tumor trials have rarely focused on seizures as an 
independent predictor of HRQOL. For example, HRQOL measures were evaluated in 243 patients with a 
primary brain tumor of any grade.55 The EORTC QLQ-30 and BN20 revealed that patients with 
malignant tumors and poor performance status had significantly lower HRQOL scores even before 
starting any adjuvant treatment. Seizures were not reported as a factor in determining HRQOL despite 
being present in 105 patients in this trial.  A study evaluating the impact of epilepsy and AEDs in patients 
with primary brain tumors used neuropsychological testing and HRQOL measures.7  One hundred fifty-
six patients with epilepsy, but without clinical or radiologic signs of tumor recurrence for at least one year 
after histologic diagnosis, were compared to healthy controls. HRQOL was assessed by the Medical 
Outcome Study Short-Form Health Survey (MOS SF-36).  Epilepsy burden was based on seizure 
frequency and AED use. In this group, 86% of patients had epilepsy and one-half of those patients using 
an AED were seizure-free. Patients with higher epilepsy burden manifested significant reductions in 
numerous cognitive domains including information processing speed, psychomotor functioning, attention 
functioning, verbal and working memory, executive function, and HRQOL. A higher epilepsy burden was 
not associated with a decrease in physical functioning (Karnofsky Performnce scale). Reductions in all 
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cognitive domains were attributed to the use of AEDs.  Lastly, a decline in HRQOL was ascribed to the 
lack of complete seizure control.  The use of QOLIE-31 has been shown to be more sensitive than the 
FACT-Br because of its focus on seizures. A study in patients with primary brain tumors and epilepsy 
revealed that an increased frequency of seizures was an independent risk factor for poor HRQOL when 
QOLIE-31 was used.56 In patients with non-BTRE, those who reach seizure freedom reported a better 
HRQOL compared to those with a 90% or less reduction in seizures.57 
Recognizing the detrimental impact of poorly controlled seizures and AED use on HRQOL in 
patients with idiopathic or partial epilepsy 58,59, it is likely these negative consequences would be as 
significant, if not more so, in patients with LGG and epilepsy. Thus, an optimal evaluation of HRQOL in 
patients with BTRE should include seizure-specific questions as well as questions relating to treatment 
with chemotherapy or RT. It is apparent that seizure-specific questions would be important in this patient 
population as details of this frequent symptom are limited with the current tools and more detailed 
information may be beneficial in future studies.    
 
Pitfalls in the assessment of response to treatment 
There are several considerations in using seizure as an outcome measure. Some of these include how to 
reconcile a change in seizure frequency with changes in AED dosing, especially when AED dosing is 
changed concurrently with tumor-directed treatment. The change in seizure frequency, whether an 
improvement or worsening, may be difficult to parse when multiple therapies (i.e., chemotherapy/RT) and 
AED adjustments are made. Also, assessing accurate seizure numbers would remain dependent on patient 
reporting which is subject to recall bias and recognition of all seizures. In patients with cognitive deficits 
from brain tumors, AED polypharmacy and chemotherapy/RT this may prove even more difficult. 
However, seizure counting and seizure reporting by patients or their caregivers is standard in epilepsy 
drug trials. 
Evaluation of treatment response to an AED is based solely upon the ability to improve seizure 
control. Response has been defined as a 50% reduction from baseline seizure frequency. However, other 
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metrics are often assessed including seizure-free rates over a defined period of time. Time to first seizure, 
adverse effects of AED treatment, functional status and HRQOL measures are also important endpoints in 
AED drug trials.60 
The timing of seizure response has not been uniform in the studies reporting seizure control after 
treatment with RT or chemotherapy. Follow-up timing can range from a fixed time post-treatment (ie, 6 
or 12 months), or on an interval such as every 3 months. 25,33,36,61  In our opinion, assessment of seizure 
control should occur at all the standard clinical time points and should coincide with the immediate 
postoperative scan, the post-RT MRI and whenever an MRI is obtained during chemotherapy or active 
surveillance.  
 
Proposed seizure assessment tool for brain tumor trials 
Seizure control is unlikely to become the primary endpoint in a LGG clinical trial.  However, it is an 
important secondary metric as seizures can be an early indicator of tumor progression, sometimes before 
tumor growth is evident on an MRI scan.16  Furthermore, a change in seizure frequency is often the reason 
to initiate treatment, and in patients with LGG and BTRE it should be a main secondary clinical outcome 
measure to assess treatment response. Seizures and AEDs also need to be incorporated into HRQOL. 
Thus, we are proposing implementation of a new assessment tool that combines the 1989 ILAE 
classification system along with the ILAE outcome scale to quantify seizure control.  This scale is easy to 
use, can be mastered by non-neurologists and has shown excellent inter-rater reliability when compared to 
the Engel classification. 62 Some of the benefits of this scale are that seizure free patients are separated 
from those with simple partial seizures defined as auras (e.g., Class 1 vs Class 2), a critical distinction 
when assessing treatment response. Also, it simplifies the reporting of seizures to seizure days rather than 
actually reporting each seizure; seizure days are defined as any calendar day in which a seizure occurs.  A 
50% reduction from baseline seizure day frequency is also used which mirrors the reporting of a treatment 
response in epilepsy drug trials.  Although the original intent of this scale was to measure seizure 
outcomes one year after epilepsy surgery, it could be used for clinical trials in LGG patients.  Using this 
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tool an assessment of seizure control could occur easily when every MRI is performed to assess tumor 
response (Fig 1). 
The features of this assessment tool would include the following 4 items: 
1. Seizure classification; using the modified ILAE classification. 
2. Seizure frequency; using the number of seizure days from last visit. 
3. Seizure outcome; using the ILAE outcome scale. 
4. Seizure severity using the seizure specific questions in the existing brain tumor HRQOL or 
symptom burden scale. 
Seizure classification in patients with LGG would be according to the ILAE classification of either a 
secondary generalized or focal (partial) seizure. Inclusion of subtypes such as simple motor, simple 
sensory, or mixed motor/sensory would be taken into consideration to distinguish those with auras 
(simple partial seizures of short duration only perceived by the patient) from those who are seizure-free.  
The ILAE scale would provide a rating system that would identify 50% improvement or worsening from 
baseline.  As the findings could be quantified, a scale of response could be developed. For example, a 
complete response with regards to seizure assessment could be seizure freedom whereas a partial response 
would be improvement by at least one level on the ILAE scale.  With regards to HRQOL, a seizure 
specific tool would provide comprehensive data of the effect of seizures on patients with BTRE.  The 
QOLIE-31 would be one such tool.  However, the use of seizure specific questions that exist in the 
established HRQOL tools currently used in glioma trials may prove more pragmatic.   
We propose a pilot trial of this tool for existing brain tumor patients. In parallel, the treating physician 
would make an assessment of seizure burden such as whether seizure burden is better, worse, or the same 
from prior visit. We would then compare the objective data using the proposed tool and ILAE measures 
with the physician’s assessment. This would allow for assessment of efficacy of this tool in capturing 
seizure data for patients undergoing brain tumor treatment. The pilot trial would allow for a starting point 
of the assessment tool and allow for modifications prior adding it to future LGG therapeutic trials.  In 
conjunction with OS and PFS, seizure control could be used an objective outcome measure.  Lastly, the 
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use of a HRQOL measure or symptom burden scale would enhance our assessment of seizure outcome 
and, in turn, treatment outcome.   
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Figure Legend:  
Figure 1. Proposed Seizure Assessment Tool 
 
